1-4 of 4
Evan Braunstein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST

Rami S. Komrokji, Michael R. Grunwald, Evan Braunstein, J.E. Hamer-Maansson, Patricia Kalafut, John Mascarenhas
Journal: Blood
Blood (2022) 140 (Supplement 1): 6832–6834.
https://doi.org/10.1182/blood-2022-159181
Published: 2022
Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa
Journal: Blood
Blood (2022) 140 (Supplement 1): 6810–6812.
https://doi.org/10.1182/blood-2022-158144
Published: 2022
Journal Articles

Direct and Indirect Costs of Patients with Myeloproliferative Neoplasm Diseases

Jingbo Yu, Michelle Jerry, James Nelson, Taylor Marlin, Evan Braunstein, Nicole Princic
Journal: Blood
Blood (2022) 140 (Supplement 1): 5268–5269.
https://doi.org/10.1182/blood-2022-166758
Published: 2022
Journal Articles

Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Srdan Verstovsek, Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein
Journal: Blood
Blood (2022) 140 (Supplement 1): 8131–8132.
https://doi.org/10.1182/blood-2022-169426
Published: 2022